Table 2. Oligorecurrent prostate cancer: results of the univariate analyses concerning DPFS and ADT-FS.
| Median DPFS (months) | 1-year DPFS | 2-year DPFS | 3-year DPFS | Median ADT-FS | 1-year ADT-FS | 2-year ADT-FS | 3-year ADT-FS | |
|---|---|---|---|---|---|---|---|---|
| Whole population (100) | 17.7 | 64.4% | 43% | 26.6% | 20.9 | 67.4% | 47.3% | 31% |
| Initial Gleason Score | P=0.824 | P=0.956 | ||||||
| ⩽7 | 19 | 68.1% | 40.2% | 17.3% | 30.7 | 71.2% | 51.4% | 18.4% |
| >7 | 15 | 58.8% | 41.8% | 13.2% | 19.7 | 67.7% | 51.4% | 18.4% |
| D'Amico risk group (D'Amico et al, 1998) | P=0.868 | P=0.967 | ||||||
| Low/intermediate | 18 | 53.8% | 29.6% | 20.1% | 19 | 63.1% | 34.5% | 23% |
| High/very high | 13.2 | 57.2% | 40.6% | 18.9% | 19 | 65% | 47.2% | 19.2% |
| PSA-DT | P=0.06 | P=0.04 | ||||||
| <6.4 months | 9 | 39.3% | 12.8% | n.r. | 9.9 | 42.9% | 21.4% | n.r. |
| ⩾6.4 months | 20.6 | 64.5% | 45.6% | 21.7% | 25.2 | 71.5% | 51.2% | 33.5% |
| PSA pre-SBRT | P=0.28 | P=0.195 | ||||||
| <2.38 ng ml−1 | 21.1 | 62.9% | 44.1% | 29.3% | 30.7 | 69.4% | 54.9% | 38.4% |
| ⩾2.38 ng ml−1 | 16.5 | 60% | 35.2% | 18.1% | 19.5 | 64.4% | 38.9% | 18.4% |
| Time to metastasis | P=0.178 | P=0.236 | ||||||
| <43.9 months | 16.3 | 66.4% | 41.1% | 29.6% | 20.9 | 76.4% | 49.9% | 36.1% |
| ⩾43.9 months | 12.9 | 54.3% | 37% | 17.5% | 19.1 | 59.6% | 44.4% | 22.2% |
| Lymph node vs bone | P=0.356 | P=0.605 | ||||||
| Lymph node | 21.4 | 63.2% | 39.5% | 17.3% | 23.1 | 69.6% | 48.3% | 30.6% |
| Bone | 11 | 20.2% | n.r. | n.r. | 10.7 | 29.6% | n.r. | n.r. |
| Number of metastases treated | P=0.16 | P=0.56 | ||||||
| One | 13.7 | 59% | 37.1% | 21% | 19.7 | 67.1% | 44.6% | 33% |
| More than one | 33 | 68.9% | 38.4% | 23.1% | 33.3 | 69.7% | 39.6% | 25.9% |
| BED | P=0.51 | P=0.597 | ||||||
| <116 Gy | 13.5 | 57.4% | 43.6% | 15.9% | 21 | 71.1% | 44.2% | 40.8% |
| ⩾116 Gy | 20.2 | 61.2% | 44.1% | 32.4% | 26.5 | 61.9% | 53.1% | 45.5% |
| Prophylactic pelvic RT | P=0.19 | P=0.47 | ||||||
| No | 15.7 | 57% | 37% | 15.8% | 19.7 | 65.7% | 45.7% | 29.4% |
| Yes | 28 | 100% | 67.1% | 33.5% | 26.5 | 100% | 70.1% | 35.9% |
| Concomitant ADT (to SBRT) | P=0.43 | P=0.35 | ||||||
| No | 13.3 | 49.2% | 36.9% | 20.6% | 19.1 | 56.3% | 41.1% | 21.7% |
| Yes | 23.5 | 94% | 44.9% | 9.9% | 25.2 | 98.4% | 45.5% | 37.9% |
Abbreviations: ADT=androgen deprivation therapy; ADT-FS=androgen deprivation therapy-free survival; BED=biologically effective dose; DPFS=distant progression-free survival; DT=doubling time; n.r.=not reached; PSA=prostatic-specific antigen; RP=radical prostatectomy; SBRT=stereotactic body radiation therapy.